Roche's Obinutuzumab and BMS's Lenalidomide Combination Achieves 49% PFS in a Phase 2 Study of Follicular Lymphoma
S1608 Clinical Trial Design for Addressing High-Risk Follicular Lymphoma
The S1608 (NCT03269669) Phase 2 clinical trial, led by the National Cancer Institute (NCI) and the SWOG Cancer Research Group, was the first randomized trial conducted on patients in the POD24 ('Progression of Disease within 24 months') group, who are early-relapse patients. Follicular Lymphoma (FL) has a poor prognosis, with a 5-year survival rate of less than 50% for POD24 patients who relapse within 2 years after initial treatment, representing a significant unmet medical need. This trial was meticulously designed to compare standard chemotherapy plus obinutuzumab with a non-chemotherapy targeted therapy combination of lenalidomide and umbralisib in a 1:1:1 ratio.
Remarkable Progression-Free Survival Results with Lenalidomide Combination
The most notable aspect of the clinical results is the strong therapeutic efficacy demonstrated by the lenalidomide and obinutuzumab (L+O) combination. At the median follow-up of 49 months, the 4-year progression-free survival (PFS) rate for the lenalidomide combination group was 49%, significantly outperforming the chemotherapy combination group (Chemo+O) at 41% and the umbralisib combination group (U+O) at 28%. This demonstrates that even without using highly toxic conventional cytotoxic chemotherapy, excellent clinical benefits can be maintained long-term through a combination with an immunomodulatory drug (IMiD).
Analysis of Umbralisib Safety Issues and Market Withdrawal
In contrast, the umbralisib and obinutuzumab (U+O) combination, supplied by TG Therapeutics (TGTX), achieved a complete remission (CR) rate of 52%, but the 4-year PFS was only 28%. This aligns with the fact that umbralisib ('Ukoniq') was voluntarily withdrawn from the market by the FDA in June 2022 due to safety concerns, including an increased risk of death observed in a separate chronic lymphocytic leukemia (CLL) clinical trial. The inherent toxicity management limitations of the PI3K inhibitor class are reflected in the long-term survival indicators of this S1608 study, re-emphasizing the importance of verifying the safety profile in the development of future targeted therapies.
Improvement in Patient Quality of Life and Potential Paradigm Shift in Standard Treatment
These clinical results provide a foundation for immunomodulatory therapies, such as lenalidomide, to replace highly toxic chemotherapy and become a new standard of care for high-risk follicular lymphoma patients. While the chemotherapy combination group had the highest complete remission rate at 64%, the lenalidomide combination group may be a better alternative considering long-term disease control and patient tolerability. In particular, given the high proportion of elderly patients with lymphoma, a chemo-free strategy that reduces toxicity while increasing progression-free survival is expected to have a positive impact on improving patient survival and reducing healthcare costs.
These Phase 2 clinical trial results demonstrate the long-term efficacy of non-chemotherapy combinations, excluding chemotherapy, in the global follicular lymphoma treatment market, which is estimated at approximately $3.28 billion in 2025, and thus have significant commercial value. The 4-year PFS of 49% achieved by the combination of Roche's obinutuzumab and BMS's lenalidomide, compared to 41% in the chemotherapy control group, provides strong evidence to revise the second-line standard treatment guidelines for high-risk patients. In contrast, the 28% PFS shown by the TG Therapeutics' umbralisib combination re-demonstrates the limitations of the PI3K inhibitor class due to safety issues, and will accelerate the trend of market funds shifting to bispecific antibody and CAR-T pipelines. Researchers are expected to focus on developing personalized therapies by identifying early-relapse high-risk patients using genetic markers such as m7-FLIPI and matching them with the optimal non-chemotherapy regimen early on. This will avoid the toxicity risks of conventional chemotherapy while creating differentiated clinical data competition with subsequent competing drugs, leading to a medium- to long-term impact on the market landscape.
Source: ClinicalTrials.gov (api_ct)